FY2022 Financial Results Presentation

from the beginning

FY2022 Financial Results Presentation

Forward-Looking Statements

1.FY2022 Financial Results

Overview of FY2022 Results

Overview of FY2022 Results

Core Operating Profit

Profit Attributable to Owners of the Company

Revenue: Business Units (incl. Forex Impact)

Revenue: Major Products in Japan

2.Business Update

Progress towards “Maximize 3ADCs

Revenue

SalesIncreasesinceLaunch

Performance in Each Region (US, EU)

Performance in Each Region (Japan, ASCA)

Progress towards “Profit growth for current business and products

LIXIANA: Growth in Each Country/Region

LIXIANA: Growth in Japan

Enhance Product Portfolio

Other Initiatives in Each Region

Progress towards “Create shared value with stakeholders

Shareholder Returns: Forecast of Annual Dividend in FY2022

3.R&D Update

FY2022 R&D achievement

Progress towards “Maximize 3ADCs

Transform the course of HER2+ BC

Pioneer HER2 low BC as a new clinically meaningful patient segment -1

Pioneer HER2 low BC as a new clinically meaningful patient segment -2

Expand leadership across other HER2 targetable tumors

Accelerated combination development with Our Assets

Progress in FY2022: NSCLC -1

Progress in FY2022: NSCLC -2

Progress in FY2022:Breast Cancer

HERTHENA-Lung01Study

Progress towards “Identify and build pillars for further growth

Progress in FY2022 -1

Progress in FY2022 -2

New Therapies for Hematological Cancers: AML

New Therapies for Hematological Cancers: ATLL

Current Development Status of COVID-19 mRNA vaccine

Other Progress in FY2022

ASCO 2023

ASCO Highlights 2023: IR conference call

News Flow

FY2023 News Flow

4.5-Year Business Plan Update

Strategic Pillars for the 5-Year Business Plan (FY2021-FY2025)

5-Year Business Plan: Progress in FY2021-FY2022 -1

5-Year Business Plan: Progress in FY2021-FY2022 -2

Expectation on achieving FY2025 KPIs(as of 2023 Apr.)

Expectation on OncologyRevenue(as of 2023 Apr.)

Profit Share Increase for ENHERTU and Dato-DXd

3ADC launch plan

From “3 and Alpha

Well-balanced Investment for Growth and Shareholder ReturnsCash Allocation

Expectation on achieving FY2025 KPIs(as of 2023 Apr.)

@

5.FY2023 Forecast

FY2023Forecast

Increase Annual Dividend in FY2023

@6.Appendix

Study list in 3ADC launch plan (slide #53) -1

Study list in 3ADC launch plan (slide #53) -2

Major R&D Milestones (3ADCs)

Major R&D Milestones (Alpha)

Major R&D Pipeline: 3ADCs

Major R&D Pipeline: Alpha

@

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5